OmeCare provides physicians and their patients with genetic information to improve or maintain health and wellness. The company's mobile health applications merge artificial intelligence and deep learning with personal genetic information that provides personalized health and wellness guidance.
Research containing OmeCare
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned OmeCare in 2 CB Insights research briefs, most recently on May 25, 2021.
Expert Collections containing OmeCare
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
OmeCare is included in 2 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
OmeCare has filed 45 patents.
Computing input devices, Capacitors, Pointing devices, Display devices, Stationery
Computing input devices, Capacitors, Pointing devices, Display devices, Stationery
Latest OmeCare News
Jul 3, 2023
Key Players Ancestry, Gene By Gene, Ltd. (FamilyTree DNA), 23andMe, Inc., Myriad Genetics, Inc., Mapmygenome, Color Genomics, Inc., Futura Genetics, Helix OpCo LLC, MyHeritage Ltd., Pathway Genomics, Amgen, Inc., Positive Biosciences, Ltd., Diagnomics, Inc., Toolbox Genomics, SomaLogic, Inc., Inui Health (formerly Scanadu), Xcode Life, AgeCurve, QuickCheck Health, Biomeb, and Others Report Highlights By Applications, the market is segmented into ancestry, diagnostics, genetic relatedness, and sports nutrition and health. In 2022, the genetic-relatedness segment will rule the market, taking 22% of the market's total revenue share. The field is driven by the rising popularity of prenatal, maternity, and paternity tests. Paternity test kits are available online for free, but they are not allowed to be used. Use of DTC genetic testing by several clients to know more about their hereditary geography and identify their lost relatives and cousins. Nevertheless, the Sports Nutrition & Health category is projected to grow at a highest CAGR throughout the estimated year. The FIMS Scientific Commission has considered the effects of DTC testing on young athletes as well as the requirement for education for practitioners of sport and exercise medicine, which is fueling the market's expansion. In the field of nutritional genomics, a person's diet can impact how genetic proof manifests in them. Genetic factors could affect how a person digests food and reacts to nutrients and other bioactive components. Market Dynamics The acceptance of genealogy services increasing among patients as the cost of sequencing is declined The sequencing cost and the cost of genomics have overall decreased due to several recent technological advancements. Sequencing is a crucial and insignificant process in genomics. Additionally, impacted populations and a rise in the prevalence of chronic diseases are also included. Due to expanding the genomic applications and favorable regulations of the government in developing countries gives variety of opportunities to the market players. In basic biological explorations and altering healthcare systems, CGH, FISH, microarray, karyotyping, and gene-editing techniques have significantly influenced. The market is expanding as a result of increased pressure from demographics and a rise in the prevalence of chronic diseases. Restraints Market limitations included a lack of skilled labor and client awareness of genetics Corporate growth is prohibited by the high cost of genomic equipment. In contrast, the development of the market is anticipated to be slowed in developed countries like China, Japan, and India due to a lack of skilled workers and expertise. This situation revealed the shortage of skilled employees in the genomics sector, which restricted the growth of this market. Due to strict regulatory environment for the development of new products and the requirement for better, safer and earlier detection tools to give patients effective therapy also hindered the market growth. Opportunities In Personalized and Specialized Medicine, the utilization of genomics A wide range of prospects for genomic companies is expected to rise with the growth of the personalized medicine industry. In the pharma sector, personalized medicine research is becoming more popular. Doctors can identify a patient's special requirements with the help of personalized medicine and recommend the medicine and treatments needed to fulfill those demands. A better standard of care can be assured by this process. Likewise, advancements in gene therapy are also anticipated to allow specialists to treat a medical condition by introducing a gene into an individual's cell, thereby dispensing with the need for present drugs and treatments. Due to the benefits of reducing expenses, patient compliance, drug security, premature ailment detection, and therapy modification personalized medical therapy increases their acceptance. Related Reports Genotyping Market - The global genotyping market size was valued at USD 16.9 billion in 2022 and it is expanding around USD 67.60 billion by 2032 with a CAGR of 14.87% from 2023 to 2032. Direct-to-consumer Genetic Testing Market - The global direct-to-consumer genetic testing market was valued at USD 2.18 billion in 2022 and it is expanding around USD 19.87 billion by 2032 with a CAGR of 24.73% from 2023 to 2032. Short-read Sequencing Market - The global short-read sequencing market was valued at USD 6.3 billion in 2022 and it is expanding around USD 36 billion by 2032 with a CAGR of 19.04% from 2023 to 2032. Browse our Brand New Journal@ https://www.towardshealthcare.com Recent Development April 2020, In order to investigate potential genetic hints for COVID-19, Ancestry DNA said that it was going to utilize its customer genomics database (with the patient's agreement). July 2020, The IVNS1ABP gene area in males has been linked to COVID-19 vulnerability, according to the study. This clarified why the viral illness had more severe consequences on men than on women. Market Segmentation Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/3018 You can place an order or ask any questions, please feel free to contact at firstname.lastname@example.org | +1 9197 992 333 About Us Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. For Latest Update Follow Us:
OmeCare Frequently Asked Questions (FAQ)
When was OmeCare founded?
OmeCare was founded in 2008.
Where is OmeCare's headquarters?
OmeCare's headquarters is located at 6777 Nancy Ridge Drive, San Diego.
What is OmeCare's latest funding round?
OmeCare's latest funding round is Series E.
How much did OmeCare raise?
OmeCare raised a total of $40M.
Who are the investors of OmeCare?
Investors of OmeCare include IBM Watson Group, Edelson Technology Partners and Founders Fund.
Who are OmeCare's competitors?
Competitors of OmeCare include Helix and 4 more.
Compare OmeCare to Competitors
Color operates as a healthcare technology company democratizing access to genetic information. It offers color tests for patients to detect hereditary cancers such as breast, colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers. Color was formerly known as Color Global. It was founded in 2014 and is based in Burlingame, California.
Ancestry focuses on family history and consumer genomics. The company offers services to allow individuals to discover their family history and gain insights from their deoxyribonucleic acid (DNA), such as their ethnicity and personal traits. It primarily serves individuals interested in personal discovery and understanding their family history. It was formerly known as The Generations Network. It was founded in 1983 and is based in Lehi, Utah.
Genomelink develops a personal discovery platform where people store deoxyribonucleic acid (DNA) data to access more insights, products, and medical research. The company platform allows the member to upload their DNA data file and discover their identities and traits. It was founded in 2017 and is based in Berkeley, California.
Hematotypes is a medical technology company dedicated to improving the way cancers of the blood, lymphoma, and leukemia are identified.
WeGene is dedicated to providing consumer genetic testing and personalized healthcare services through intelligent hardware, offline services, and online communities. Its report consists of ancestry analysis, genetic disease and health risk information, nutritional genomics, and athletic and drug responses analysis. WeGene is also committed to working with researchers to dig deep into genome data to promote scientific research while allowing users to further benefit from their own genome data. The company was founded in 2014 and is based in Shenzhen, China.
Luna offers a health and genomic data platform owned by its community of personal health information donors. It empowers individuals to share their health data for medical research and the greater good of the community. The company was founded in 2017 and is based in San Diego, California.